Undisclosed allogeneic TCR-iPS-T-cell therapy / Anocca, Shinobi Therap - LARVOL DELTA

Shinobi Therapeutics Secures $59M Grant from the Japanese Agency for Medical Research and Development (PRNewswire) - "Shinobi Therapeutics...announced that it has been awarded up to $59M in non-dilutive grant funding by the Japanese Agency for Medical Research and Development (AMED). The grant will be used to support the development of Shinobi's lead program, an iPS-T cell therapy targeting GPC3+ solid tumor cancers....Shinobi also announced an extension of its Series A round, bringing the company's total funding to $119M, with the addition of Yosemite and Mitsubishi UFJ Capital as investors."

Financing • Oncology • Solid Tumor

Anocca AB and Shinobi Therapeutics Announce Strategic Partnership to Develop Allogeneic TCR-T Cell Therapies in Oncology (GlobeNewswire) - "Anocca AB...today announced a strategic partnership to use Shinobi’s proprietary immune evasive iPS-T cell platform with novel candidate TCRs, discovered and validated by Anocca, to develop a new class of off-the-shelf allogeneic TCR engineered iPS-T-cell therapies (TCR-iPS-T) for solid tumors."

Licensing / partnership • Solid Tumor